Loading
A phase 3 trial of pemetrexed and pembrolizumab in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors is a phase 3, interventional study registered as NCT05055908 by Hunan Province Tumor Hospital, with a registry enrolment figure of 12000 participants, started 2021-10-01 and due to reach its primary completion in 2025-07-01. Interventions recorded: Pemetrexed plus Pembrolizumab; Pembrolizumab; Pemetrexed. Conditions listed: Lung Cancer. Primary outcome: Correlation between Adverse events (AEs) and gene profile. Lung eligibility wording from the registry: "Histologically or cytologically confirmed lung cancer". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Pembrolizumab, Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.